Genlight
Hangzhou, ChinaSee on the mapFounded 2020
- Brain-computer interfaces
- Neuromodulation
- Series D
- Epilepsy
Genlight is a Hangzhou-based medical technology company focused on commercializing advanced technologies in neuroscience and neurosurgery. It develops brain neuromodulation and medical laser platforms, with device solutions for neurological conditions including epilepsy.
- RaisedTotal raised
- $31.4M
- Sep 2026Latest priced round, Sep 2026
- Series D
- Investors
- 15
- Founded
- 2020
- Employees
- 101–250
reccy insights
Genlight’s most recent listed financing milestone is a Series D dated Sep 7, 2026, with Cybernaut Investment Group, Ningbo State-owned Assets, and Tianqi Hengsong Fund identified as lead investors. Earlier, a Series C was dated May 12, 2026; Qiming Venture Partners and Sherpa Healthcare Partners are associated with that round across the available company information. The company develops technologies spanning brain neuromodulation and medical lasers. Its product portfolio includes LaserRO™, an MRI-monitored semiconductor laser treatment system; S-Deep™, an intracranial deep electrode; and Epilcure™, an implanted closed-loop responsive neurostimulation system for epilepsy. Epilcure™ has entered China’s special review program for innovative medical devices, while LaserRO™ and S-Deep™ have Class III medical device registration certificates. The company also describes a portfolio of more than 100 invention patents, in addition to utility model, design, and PCT filings.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Genlight distinct
- 01Combines brain neuromodulation and medical laser technology platforms for neurological care.
- 02LaserRO™ and S-Deep™ have received Class III medical device registration certificates.
- 03Epilcure™ is an implanted closed-loop responsive neurostimulation system for epilepsy and has entered China’s special review program for innovative medical devices.
- 04Reports more than 100 invention patents, alongside utility model, design, and PCT filings.
- 05Pursues industry-academic collaboration and has been recognized as a high-growth and investment-value innovation company in Zhejiang.
Technology & products3
- LaserRO™
MRI-monitored semiconductor laser treatment system; the company reports a Class III medical device registration certificate.
- Epilcure™
Implanted closed-loop responsive neurostimulation system for epilepsy; it has entered China’s special review program for innovative medical devices.
- S-Deep™
Intracranial deep electrode; the company reports a Class III medical device registration certificate.
Funding
- Series DSep 2026Cybernaut Investment Group, Ningbo State-owned Assets, Tianqi Hengsong Fund
- Series CMay 2026
- Venture RoundJan 2023
Investors7
- Yuanjing Capital
- Cybernaut Investment Group
- Ningbo State-owned Assets
- Tianqi Hengsong Fund
Similar companies
About Genlight
- Products
- LaserRO™, Epilcure™, S-Deep™
- Leadership
- Cao Peng
- Focus areas
- Neuroscience, neurosurgery, medical devices, neuromodulation, BCI, epilepsy, medical lasers, implantable devices
- Headquarters
- Hangzhou, China
- Founded
- 2020
- Employees
- 101–250
- Status
- Active · private